Prior authorization automation for dermatology practices pays back through staff hours saved on biologic and specialty-drug PAs, fewer denials that need rework, and faster approvals that keep patients from abandoning treatment before they start. A practice submitting 15-20 biologic PAs a week can reclaim 400-500 staff hours a year, and once you add denial rework and retained biologic revenue, the return usually lands at several multiples of what the automation costs.
How Much Biologic PA Work Is a Dermatology Practice Actually Doing?
Ask any derm practice administrator and you'll hear the same complaint: biologics generate more prior authorization work than almost anything else on the schedule. Psoriasis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa patients on drugs like Dupixent, Skyrizi, Cosentyx, or Humira all need PAs — for the initial start, for step-therapy documentation, and again at renewal.
The 2024 AMA Prior Authorization Physician Survey found physicians and their staff complete an average of 39 PA requests per physician per week, and 40% of physicians employ staff who work on prior authorization exclusively (AMA, 2024). Biologic and specialty-drug requests take longer than routine ones because they require step-therapy proof, clinical notes, lab values, and photos of affected skin. MGMA's research backs this up: 60% of practices report at least three employees touch a single PA before it's resolved, and more than a third of practices say individual requests regularly take 35 minutes or more of staff time (MGMA, 2025).
Layer in regulatory timing. Starting January 1, 2026, CMS's Interoperability and Prior Authorization Final Rule (CMS-0057-F) requires impacted payers to respond to standard requests within 7 calendar days and expedited requests within 72 hours, and to publish specific denial reasons (CMS, CMS-0057-F). That's good news for turnaround time, but it also means practices need to track deadlines and respond to payer requests faster than a manual, spreadsheet-and-fax workflow can reliably manage. For a mid-size derm practice running 15-20 biologic PAs a week, that's roughly 750-1,000 a year — each one a candidate for delay, denial, or staff burnout.
The Direct Labor Math Behind Prior Authorization Automation for Dermatology Practices
The ROI formula is simple to state and worth running with your own numbers: weekly PA volume × minutes per PA × loaded hourly staff cost × 52 weeks.
Take a practice processing 18 biologic and specialty-drug PAs a week, averaging 35 minutes of staff time each (submission, chart pulls, payer portal work, phone holds, and follow-up calls). That's 630 minutes, or 10.5 hours, a week — roughly 500 hours a year. The Bureau of Labor Statistics puts median pay for medical secretaries and administrative assistants at roughly $19-23 an hour before benefits (BLS Occupational Outlook Handbook); loaded for payroll tax and benefits, that's closer to $26-29 an hour. At $27 an hour, 500 hours of PA labor costs a practice roughly $13,500 a year — and that's before counting denials, overtime during volume surges, or the cost of a second staff member added just to keep up.
This is the number CFOs care about most, because it's the easiest to defend in a budget meeting: hours multiplied by a rate you already know. It's also the number that moves fastest when automation takes over first-pass submission, data entry, and status checks, since that's where most of the manual minutes go.
The math also shifts during volume surges — flu season staffing gaps, a provider going on leave, or a new biologic launch that suddenly pulls a wave of step-therapy paperwork. Practices without slack in their PA staffing often cover the overflow with overtime or a temp hire, both of which run above the base loaded rate. Automation doesn't eliminate volume swings, but it removes the need to staff up for them, since the software handles the extra submissions at the same marginal cost as a normal week.
Denials Add a Second Layer of Cost
A submitted PA isn't the end of the story — a denied one costs more. CAQH's 2024 Index found a manually processed prior authorization transaction costs an estimated $11.12, compared with $2.11 for one processed electronically — a gap of roughly $9 per transaction that widens further once a denial forces rework (CAQH 2024 Index). MGMA estimates each denied PA costs a practice an average of $31 in additional rework labor — pulling the chart again, gathering more documentation, resubmitting, and sometimes scheduling a peer-to-peer review with the prescribing dermatologist (MGMA, 2025).
If a practice runs 900 biologic PAs a year and even 15% come back denied on first submission, that's 135 denials times $31 — about $4,200 a year in pure rework cost, on top of the original labor. Push the denial rate to 20%, which isn't unusual for biologics with strict step-therapy rules, and rework costs climb past $5,500. None of this counts the dermatologist's own time on a peer-to-peer call, which typically isn't billable and pulls a provider out of patient visits.
Automation reduces this in two ways: it catches missing documentation before submission, so fewer requests get denied on a technicality, and it standardizes the clinical justification language payers expect for biologics — which is often the actual reason a request bounces back. Most biologic denials in dermatology trace back to a handful of repeat causes: a missing letter of medical necessity, incomplete documentation of failed topical or systemic therapies, or a mismatch between the diagnosis code and the payer's coverage policy for that specific drug. None of those require clinical judgment to catch — they require someone, or something, checking the payer's own criteria against the chart before the request goes out.
The Revenue Side: What Slow Approvals Cost in Abandoned Treatment
Labor and rework are the easy math. The harder number — and often the bigger one — is what a practice loses when a patient simply doesn't start the biologic they were prescribed.
Research on psoriasis and psoriatic arthritis patients found that prior authorization requirements are associated with significantly longer waits for biologic approval, and that delay itself is a known driver of treatment abandonment: patients get discouraged, symptoms worsen, or they get talked out of therapy by a pharmacy call before the approval ever comes through (JAAD, 2022; AJMC). Every abandoned biologic start represents a lost follow-up visit cadence, lost lab and monitoring revenue, and a patient who may not come back for their next flare.
For a practice with, say, 200 new biologic starts a year, even a 10-15% abandonment rate tied to PA delay means 20-30 patients a year who never begin therapy at your practice — some of whom churn to another provider entirely. Faster approval turnaround doesn't just protect that visit revenue; it protects the referral relationships that sent the patient in the first place, since referring physicians notice when their patients get stuck in PA limbo.
Where Honey Health's Prior Authorization Agent Fits Into the Payback Math
This is where automation earns its keep on both sides of the ledger. Honey Health's Prior Authorization agent handles the parts of the PA workflow that eat staff hours — pulling the chart data, matching it to payer-specific criteria, assembling step-therapy documentation, submitting the request, and tracking status so nobody's calling a payer's hold line to check on it. It doesn't replace clinical judgment; it removes the manual keystrokes and phone time around it.
Run the payback math conservatively: if automation reclaims 60-70% of the roughly 500 hours a mid-size derm practice spends on biologic PA labor, that's $8,000-9,500 a year in direct labor savings alone. Add a modest reduction in denial rework — cutting denials by even a third saves another $1,500-2,000 — and factor in even one or two retained biologic starts that would have otherwise abandoned, and most practices clear their annual subscription cost within the first few months, with the labor and denial savings alone often covering it well before the abandoned-revenue upside even shows up. That's the case for anchoring the ROI conversation in hours and denials first, and treating retained biologic revenue as the upside on top. It's also why most practices evaluating prior authorization automation for dermatology practices start the conversation with their PA coordinator's calendar, not a demo — the labor math alone usually makes the case.
The Soft Returns: Burnout, Turnover, and Patient Access
Not every return on this shows up on a spreadsheet. Staff who spend their day on hold with payers, resubmitting the same documentation twice, are staff who burn out and leave — and replacing a PA coordinator costs a practice weeks of ramp time on top of recruiting fees. The AMA survey found that 13 hours a week of combined physician and staff time goes into prior authorization work across specialties (AMA, 2024); in a derm practice heavy on biologics, that number skews higher, and it's disproportionately absorbed by the same one or two staff members who "own" PA.
There's a patient-access angle too. A patient with moderate-to-severe psoriasis or hidradenitis suppurativa waiting three extra weeks for a biologic approval isn't just a delayed data point — they're living with a flare that's affecting their job, their sleep, and their confidence. Shrinking that wait doesn't require a new drug or a new specialist. It requires the paperwork moving faster, and that's squarely a workflow problem, not a clinical one. For a CFO weighing prior authorization automation for a dermatology practice against another hire, that's the framing that matters: the labor savings alone often justify the subscription, and the reduced burnout and faster patient access come with it at no extra cost. Turnover on a PA-heavy front or back office role also carries a real dollar cost, even if it never shows up on a P&L line labeled "prior authorization": recruiting, onboarding, and the productivity dip while a replacement learns each payer's quirks typically runs into several thousand dollars per departure, on top of the overtime other staff absorb in the gap.
Frequently Asked Questions
How is the ROI of prior authorization automation calculated for a dermatology practice?
Start with weekly PA volume times average minutes per PA times loaded hourly staff cost times 52 weeks to get baseline labor cost. Then add denial rework cost (volume times denial rate times average rework cost) and any retained revenue from patients who no longer abandon treatment due to delay. Compare the total to the subscription cost of the automation tool.
How many biologic prior authorizations does a typical dermatology practice process?
It varies by practice size and patient mix, but practices with a significant psoriasis, psoriatic arthritis, atopic dermatitis, or hidradenitis suppurativa population commonly process 15-20 biologic and specialty-drug PAs a week, or roughly 750-1,000 a year, once new starts and renewals are combined.
How much staff time does a single biologic PA take?
MGMA data shows more than a third of practices report individual PA requests taking 35 minutes or more of staff time, and biologic requests tend to run on the higher end of that range because of step-therapy documentation and clinical justification requirements.
Does prior authorization automation actually reduce denials?
Automation reduces denials most effectively when it catches missing documentation before submission and standardizes the clinical justification language a payer expects — the two most common reasons biologic PAs bounce back. It doesn't eliminate payer-side denials tied to plan design, but it removes the avoidable, documentation-driven ones.
What's a realistic payback period for prior authorization automation in a derm practice?
Most practices that automate biologic and specialty-drug PA recover their subscription cost within a few months once labor hours and denial rework are counted, with retained biologic revenue from fewer abandoned treatments adding further upside over the course of a year.
Is the CMS 2026 prior authorization rule relevant to dermatology practices?
Yes. Starting January 1, 2026, CMS-0057-F requires impacted payers to respond to standard PA requests within 7 days and expedited ones within 72 hours, and to publish specific denial reasons. That tighter turnaround puts more pressure on practices to track deadlines and respond quickly, which a manual process struggles to keep pace with.
